BMRA Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -72.83% compared to Biomerica's net margin of 5.12%. Biomerica's return on equity of -77.23% beat InfuSystems Holdings's return on equity of 2.8%.

Biomerica has a consensus price target of --, signalling upside risk potential of 3948.58%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 78.57%. Given that Biomerica has higher upside potential than InfuSystems Holdings, analysts believe Biomerica is more attractive than InfuSystems Holdings.

Biomerica has a beta of -1.042, which suggesting that the stock is 204.193% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.098%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.8M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Biomerica's net income of -$1.3M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Biomerica's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 124.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 0.98x versus 1.29x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -72.83% compared to Biomerica's net margin of -18.58%. Biomerica's return on equity of -77.23% beat Retractable Technologies's return on equity of -16.83%.

Biomerica has a consensus price target of --, signalling upside risk potential of 3948.58%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Biomerica has higher upside potential than Retractable Technologies, analysts believe Biomerica is more attractive than Retractable Technologies.

Biomerica has a beta of -1.042, which suggesting that the stock is 204.193% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.939, suggesting its more volatile than the S&P 500 by 93.884%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Biomerica quarterly revenues are $1.8M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Biomerica's net income of -$1.3M is higher than Retractable Technologies's net income of -$1.9M. Notably, Biomerica's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 0.98x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -72.83% compared to Biomerica's net margin of -4291.67%. Biomerica's return on equity of -77.23% beat Catheter Precision's return on equity of -65.84%.

Biomerica has a consensus price target of --, signalling upside risk potential of 3948.58%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 354.55%. Given that Biomerica has higher upside potential than Catheter Precision, analysts believe Biomerica is more attractive than Catheter Precision.

Biomerica has a beta of -1.042, which suggesting that the stock is 204.193% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.8M, which are larger than Catheter Precision quarterly revenues of $96K. Biomerica's net income of -$1.3M is higher than Catheter Precision's net income of -$4.1M. Notably, Biomerica's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 0.98x versus 1.17x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -72.83% compared to Biomerica's net margin of -17.98%. Biomerica's return on equity of -77.23% beat Xtant Medical Holdings's return on equity of -35.98%.

Biomerica has a consensus price target of --, signalling upside risk potential of 3948.58%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 350%. Given that Biomerica has higher upside potential than Xtant Medical Holdings, analysts believe Biomerica is more attractive than Xtant Medical Holdings.

Biomerica has a beta of -1.042, which suggesting that the stock is 204.193% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Biomerica's net income of -$1.3M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Biomerica's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 0.98x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.